Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm Group™ Presents The ‘JCA Mauvernay Award 2013’

Published: Tuesday, October 08, 2013
Last Updated: Monday, October 07, 2013
Bookmark and Share
Doctors Kitabayashi and Yano will receive awards during the General Assembly of the 72nd Annual Conference of the JCA in Yokohama.

Debiopharm Group™ (Debiopharm) will be presenting the ‘JCA-Mauvernay Award’ on October 5, to Doctors Issay Kitabayashi from Tokyo National Cancer Center Research Institute for his basic research on ‘Molecular study of acute myeloid leukemia and its application for therapy’ and Seiji Yano from Kanazawa University for his applied research on ‘Circumvention of molecular targeted drug resistance in lung cancer’.

Doctors Kitabayashi and Yano will receive their Awards during the General Assembly of the 72nd Annual Conference of the Japanese Cancer Association (JCA) in Yokohama on the following theme: ‘Cancer research providing hope to fight against cancer’.

Dr. Tetsuo Noda, President of the JCA and a Debiopharm Group representative will present the trophies to both scientists.

“The selecting committee members chose the nominees for the high standard and application possibilities of their research. Debiopharm is honored to be part of this Award with the JCA and wishes both scientists success with their work,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

Dr Kitabayashi focuses on the molecular study of the basis of the development of acute myeloid leukemia (AML). He shows that it is related to chromosomal rearrangements modifying the function of genes involved in transcription and hematopoiesis (AML1, PML, MOZ).

Molecular drugs like EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors (TKIs) show dramatic effects in lung cancer patients. However resistance to EGFR-TKIs is a major problem in current clinical practice.

Dr Yano aims to conduct clinical trials to elucidate and overcome the molecular mechanisms involved in the resistance to lung cancer drugs and to establish treatments to overcome it.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curis and Debiopharm Announce Initiation of Phase I-II Clinical Study of HSP90 Inhibitor
Study to test Debio 0932 in patients with advanced non-small cell lung cancer.
Friday, August 17, 2012
Debiopharm and Vifor Pharma Sign an Exclusive Agreement
Distribution and commercialization of Pamorelin® LA in Switzerland.
Monday, May 21, 2012
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!